We serve Chemical Name:D-Glucopyranose, oligomeric, C12-14-alkyl glycosides CAS:157707-88-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:D-Glucopyranose, oligomeric, C12-14-alkyl glycosides
CAS.NO:157707-88-5
Synonyms:EINECS 500-395-4
Molecular Formula:N/A
Molecular Weight:N/A
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like EINECS 500-395-4 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 500-395-4 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 500-395-4 Use and application,EINECS 500-395-4 technical grade,usp/ep/jp grade.
Related News: A number of UK citizens had trouble reaching the muster point in time for the first flight out because of road blocks and other restrictions in place in Wuhan. D-Glucopyranose, oligomeric, C12-14-alkyl glycosides manufacturer Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. D-Glucopyranose, oligomeric, C12-14-alkyl glycosides supplier Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. D-Glucopyranose, oligomeric, C12-14-alkyl glycosides vendor A number of UK citizens had trouble reaching the muster point in time for the first flight out because of road blocks and other restrictions in place in Wuhan. D-Glucopyranose, oligomeric, C12-14-alkyl glycosides factory Multinational drugmakers usually cut the price of drugs when they go off-patent and face competition from generic versions, but such price drops were slow to happen in China, partially because many local drugmakers were unable to develop high-quality generic drugs to compete with off-patent branded drugs.
